Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Bagot
Martine
M
Department of Dermatology, Hôpital Henri Mondor, Créteil, France. martine.bagot@hmn.aphp.fr
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene; D008727:Methotrexate